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incidence and epidemiology
Neuroendocrine gastroenteropancreatic tumors (GEP-NETs)
constitute a heterogeneous group of tumors with their origin in
neuroendocrine cells of the embryological gut. Most
commonly, the primary lesion is located in the gastric mucosa,
the small and large intestine, the rectum and pancreas. The
crude incidence has signiﬁcantly increased over the last years
and is now estimated to be 5.25/100 000/year. The prevalence
has recently been calculated to 35/100 000/year. The incidence
for small intestinal neuroendocrine tumor (NETs) (carcinoids)
is estimated to be from 0.32/100 000/year (England) to 1.12/
100 000/year (Sweden). The incidence for rectal tumors is 0.86/
100 000/year, for pancreatic 0.32/100 000/year and for gastric
NETs 0.30/100 000/year. Neuroendocrine GEP tumors can
appear at all ages, with the highest incidence being from the
ﬁfth decade onward. The exception is the carcinoid of the
appendix, which occurs with the highest incidence at ∼40
years of age. There is a slight overall higher incidence of NETs
for males (5.35) compared with females (4.76). Patients with
multiple endocrine neoplasia type 1 (MEN-1) or von Hippel–
Lindau’s disease (VHL), may have a clinical onset 15–20 years
earlier than patients with corresponding sporadic type of
neuroendocrine tumors [1].
diagnosis and pathology/molecular
biology
Patients with clinical symptoms suggestive of neuroendocrine
GEP-NET should be referred to a center with special interest
in, and knowledge of, these diseases. Histological diagnosis is
mandatory in all cases and is usually obtained on surgical or
endoscopic biopsies or ultrasonography guided liver biopsies.
The family of neuroendocrine GEP-NETs constitutes a
heterogeneous group, but all share a common phenotype with
immunoreactivity for the so-called pan-neuroendocrine’
markers including chromogranin A and synaptophysin.
Neuron-speciﬁc enolase (NSE) and CD56 are often positive in
GEP-NETs, but are not speciﬁc for this tumor entity. A
detailed description of the macroscopic, microscopic and
immunohistochemical ﬁndings is mandatory to support the
diagnosis of NETs and to allow a correct classiﬁcation, staging
and grading. Speciﬁc staining for hormones, such as serotonin,
gastrin, insulin and glucagon, can be applied to conﬁrm the
source of a clinical symptomatology, but it must be pointed out
that there is no reciprocal agreement, as there can be
production of hormones without secretion. Therefore,
immunohistochemical demonstration of a hormone alone is
not proof of functionality of a NET. Immunohistochemistry for
Ki-67 (MIB-1) is mandatory to grade the tumor according to
the new World Health Organization (WHO) classiﬁcation.
GEP-NETs can be part of familial syndromes such as MEN-1,
VHL, tuberosclerosis and neuroﬁbromatosis (NF1,2). Genetic
testing should be done according to the approved methodology
and after genetic counseling. NETs arising at different
anatomical sites of the digestive system represent tumor
entities that differ in their biology and clinical presentation
(Table 1) [2].
staging and risk assessment
The new WHO classiﬁcation presented in 2010 deﬁnes the
entire group of tumors as neuroendocrine neoplasms and
divides the tumors into NET G1, NET G2 and poorly
differentiated neuroendocrine carcinoma (NEC G3) (Table 2).
The European Neuroendocrine Tumor Society has proposed a
tumor–node–metastasis staging and grading system for various
types of GEP-NETs (Tables 3–8) (II, A) [2–4]. Preoperative
staging should, whenever possible, include somatostatin
receptor scintigraphy which can nowadays be replaced by
68Gallium-DOTA-TOC/-NOC/-TATE positron emission
tomography (PET) with higher spatial resolution and
quantiﬁcation, which causes higher sensitivity and speciﬁcity.
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However, all tumors do not express a signiﬁcant number of
somatostatin type 2 receptors. Therefore, the technique should
always be complemented with computed tomography (CT) or
magnetic resonance imaging (MRI) depending on the tumor
location. PET scanning with speciﬁc tracers such as 11C-5HTP,
18F-DOPA or 18F-DG can further optimize the staging of the
disease [4–7]. Endoscopy (gastroscopy, endoscopic
ultrasonography, colonoscopy, capsule endoscopy etc.) is often
of additional value (III, A). The imaging procedures should
always be complemented with biochemical analysis of relevant
biomarkers such plasma chromogranin A (pCgA), which is a
general NET marker. In patients with poorly differentiated G3
tumors, pCgA is often normal, but plasma NSE can sometimes
be of value as a general marker. For patients with small
intestinal NETs (carcinoids), urine 5-hydroxy-indole-acetic-
acid is important and should be done in combination with the
pCgA assessments. For pancreatic NETs, the speciﬁc hormones
should be analysed in relation to clinical symptoms such
gastrin for patients with Zollinger Ellison’s syndrome, insulin
with hypoglycemic syndromes, glucagon with glucagonoma
syndrome and VIP with the Verner Morrison syndrome.
Nonfunctioning pancreatic endocrine tumors may secrete
increased levels of pCgA as well as pancreatic polypeptide (PP)
[8]. Rectal NETs are usually of the so-called nonfunctioning
type, but they often secrete hormones, such as PP, somatostatin
and PYY. The largest group of GEP-NETs, well differentiated
(NETs) of the small intestine (carcinoids), present with the
carcinoid syndrome in ∼30% of the patients, including
ﬂushing, diarrhea and endocardial ﬁbrosis. The syndrome is
caused by serotonin and peptide hormones released from liver
metastases but not from the primary small intestinal tumor, as
the hormones released to the portal vessels as metabolized in
the liver at by-pass (II, A). The 5-year survival rate for patients
with midgut carcinoid tumor has been 60% for all stages. In
dedicated centers, the 5-year survival rate now for metastatic
carcinoid tumors is ∼75%. The 5-year survival rate for patients
with endocrine pancreatic tumors is estimated to be 60%–
100% for localized disease, 40% for regional and 25% for
metastatic and 80% for all stages. Similarly, in dedicated
centers, the 5-year survival rate for metastatic pancreatic NETs
is above 60% (III, A) [9–12].
management of local/locoregional
disease
All patients with small intestinal NETs should be considered
potential candidates for curative surgery and should be
evaluated in an interdisciplinary setting including an
Table 2. Gastro entero pancreatic neoplasms: WHO Classiﬁcation (2010)
WHO 1 NET G1, Ki-67 ≤2%
WHO 2 NET G2, Ki-67 3%–20%
WHO 3 NEC G3, Ki-67 >20%
MANEC
Tumor-like lesions
NEN, neuroendocrine neoplasms; NET, neuroendocrine tumor; NEC,
neuroendocrine carcinoma; MANEC, mixed adenocarcinoma and
neuroendocrine carcinoma.
Table 3. TNM classiﬁcation for gastric endocrine tumors (European
Neuroendocrine Tumor Society)
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis In situ tumor/dysplasia (<0.5 mm)
T1 Tumor invades lamina propria or submucosa and ≤1 cm
T2 Tumor invades muscularis propria or subserosa or >1 cm
T3 Tumor penetrates serosa
T4 Tumor invades adjacent structures
For any T, add (m) for multiple tumors
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
M Distant metastases
MX Distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
TNM, tumor–node–metastasis.
Table 1. Classiﬁcation of neuroendocrine GEP tumors (GEP-NETs)
by site of origin and by hormonal activity
Intestinal neuroendocrine tumors (carcinoids, about 50% of GEP-NETs)
• with carcinoid syndrome (30% of carcinoids) ﬂushing, diarrhea,
endocardial ﬁbrosis, wheezing caused by release of serotonin
predominantly from liver metastases
• without carcinoid syndrome (70% of carcinoids)
Pancreatic endocrine tumors (PETs) (∼30% of GEP-NETs)
Nonfunctioning (45%–60% of PETs)
Functioning (40%–55% of PETs)
• Gastrinoma, excessive gastrin production, Zollinger–Ellison
syndrome
• Insulinoma, excessive insulin production, hypoglycemia syndrome
• Glucagonoma, excessive glucagons production, glucagonoma
syndrome
• VIPoma, excessive production of vasoactive intestinal peptide (VIP),
Watery diarrhea, hypokalemia–achlorhydria syndrome
• PPoma, excessive PP production, (generally classiﬁed as
nonfunctioning PETs)
• Somatostatinoma, excessive somatostatin production
• CRHoma, excessive corticotropin-releasing hormones production
• Calcitoninoma, excessive calcitonin production
• GHRHoma, excessive growth hormone-releasing hormone
production
• Neurotensinoma, excessive neurotensin production
• ACTHoma, excessive production of adrenocorticotropic hormone
• GRFoma, excessive production of growth hormone-releasing factor
• Parathyroid hormone-related peptide tumor
GEP-NETs, neuroendocrine gastroenteropancreatic tumors.
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experienced surgeon. Curative resection of the primary tumor
and locoregional lymph node metastases improves outcomes in
these patients, resulting in excellent 5- and 10-year survivals of
100% in stage 1 and stage 2 patients, and still favorable
outcomes in stage 3 disease with 5- and 10-year survivals of
more than 95% and 80%, respectively. Surgical procedures
include small intestinal resection or right hemicolectomy
depending on the localization of the primary. Curative
resection also involves clearance of mesenterial and
retroperitoneal lymph node metastases by dissection around
the mesentery, preserving the intestinal vascular supply.
Resection of the primary intestinal NET and regional lymph
node metastases in patients with distant metastases (liver) is
generally advocated to prevent later development of mesenteric
ﬁbrosis, small-bowel obstruction or painful vascular
encasement. In addition, survival is prolonged in most studies,
but survival data are based on retrospective studies, which may
have a patient selection bias (patients with the best
performance status are operated). Prospective randomized
studies are needed. Large resections of the small intestinal
should be avoided as it may cause short-bowel syndrome.
Postoperative mortality should be <1% and signiﬁcant
morbidity <10% (II, A). In patients with pancreatic NETs,
indications for surgery depend on clinical symptom control,
Table 5. TNM classiﬁcation for endocrine tumors of the pancreas
(European Neuroendocrine Tumor Society)
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor limited to the pancreas and size ≤2 cm
T2 Tumor limited to the pancreas and size 2–4 cm
T3 Tumor limited to the pancreas and size >4 cm or invading
duodenum or bile duct
T4 Tumor invading adjacent organs (stomach, spleen, colon, and
adrenal gland) or the wall of large vessels (celiac axis or superior
mesenteric artery)
For any T, add (m) for multiple tumors
N Regional lymph nodes
NX Regional lymph node cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
M Distant metastases
MX Distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
TNM, tumor–node–metastasis.
Table 6. TNM classiﬁcation for endocrine tumors of lower jejunum
and ileum (European Neuroendocrine Tumor Society)
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor invades mucosa or submucosa and has a size ≤1 cm
T2 Tumor invades muscularis propria or size >1 cm
T3 Tumor invades subserosa
T4 Tumor invades peritoneum/other organs
For any T add (m) for multiple tumors
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
M Distant metastases
MX Distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
TNM, tumor–node–metastasis.
Table 7. TNM classiﬁcation for endocrine tumors of colon and rectum
(European Neuroendocrine Tumor Society)
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor invades mucosa or submucosa
T1a size ≤1 cm
T1b size 1–2 cm
T2 Tumor invades muscularis propria or size >2 cm
T3 Tumor invades subserosa, pericolic, and perirectal fat
T4 Tumor directly invades other organs/structures and/or perforates
visceral peritoneum
For any T add (m) for multiple tumors
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
M Distant metastases
MX Distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
TNM, tumor–node–metastasis.
Table 4. TNM classiﬁcation for endocrine tumors of the duodenum/
ampulla/proximal jejunum (European Neuroendocrine Tumor Society)
T Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor invades lamina propria or submucosa and has a size ≤1 cm
T2 Tumor invades muscularis propria or size >1 cma
T3 Tumor invades pancreas or retroperitoneum
T4 Tumor invades peritoneum or other organs
For any T, add (m) for multiple tumors
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
M Distant metastases
MX Distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
aTumor limited to ampulla of Vater for gangliocytic paraganglioma.
TNM, tumor–node–metastasis.
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tumor size/location, extent, malignancy and metastatic spread.
Curative surgery should be considered whenever possible even
in the presence of metastatic disease, including localized
metastatic disease to the liver if considered potentially
resectable and the patient can tolerate the surgery. The type of
surgery, the form of pancreatico-duodenal resection (Whipple’s
operation), distal pancreatic resection or a nucleation in
combination with resection, depends on the location of the
primary tumor. As the malignancy is frequent in pancreatic
NETs, adequate lymph node clearance is mandatory (III, A).
Laparoscopic resection is not recommended because of the
need for lymphadenectomy and careful inspection for
invasion/metastases. It is a general agreement not to operate on
G3 pancreatic NEC, as these tumors are widely metastasized at
the timepoint of diagnosis (III, B) [13, 14, 15].
management of advanced/metastatic
disease
Cytoreductive surgery should be considered when metastatic
disease is localized or if >70% of tumor load is thought
resectable, which may decrease endocrine and local symptoms
and might help to improve systemic treatment. There are no
randomized clinical trials comparing the efﬁcacy of
locoregional therapies and palliative liver surgery [15]. The
choice of the ablative or locoregional procedure such as
radiofrequency ablation (RFA), laser-induced thermotherapy
or selective hepatic transcatheter arterial embolization (TAE),
chemoembolization (TACE) and selective internal radiotherapy
(SIRT) depends on the local expertise, number and size of
lesions and location of liver involvement. These types of
locoregional therapies are usually used in combination with
systemic medical treatment. If bulky disease is present,
locoregional therapy is indicated early also in nonfunctioning
tumors and is used for down-staging of the disease. RFAs in
tumors <5 cm in size have shown 70%–80% symptomatic
responses with control of symptoms up to 1 year (III, B).
Selective hepatic TAE or TACE with hepatic artery occlusion
can be applied in the treatment of liver metastases from all
types of neuroendocrine G1/G2-tumors. Complete or partial
response for symptoms, tumor markers and imaging occurred
in 70%–100%, 50%–90% and 30%–50% of the patients,
respectively. The duration of symptomatic response varied
between 14 and 20 months. The procedure is contraindicated
in patients with complete portal vein thrombosis and poor
liver function. Whipple procedure is also a contraindication for
TACE/TAE since it increases the risk of morbidity. In the
absence of comparative trials, it remains unclear whether
TACE is preferred to TAE alone (III, B). Selective internal
irradiation therapy (SIRT) is still considered investigational.
Recent studies with 90Yttrium microspheres in about 200
patients with neuroendocrine tumors show objective response
rates of 50%–60% in patients with liver metastases. Most data,
however, are retrospective and derive from small phase II trials
(III, B). A randomized trial between SIRT and TACE is
warranted [16–19].
medical therapy
The use of somatostatin analogs is standard therapy in
functioning NETs of any size [20, 21]. Interferon alpha may
also be considered for symptom control in some patients and
is usually used as second line therapy due to its less-favorable
toxic proﬁle [22]. It has, sometimes, additional value as an
add-on therapy in patients with clinical syndromes that are not
controlled with somatostatin analogs. The antitumor efﬁcacy of
somatostatin analogs appears weak with respect to objective
tumor response (5%–10%). However, disease stabilization of
up to 50%–60% has been reported (III, A). In a prospective
randomized placebo-controlled trial of octreotide long-acting
release (LAR), 30 mg every 4 weeks in small intestinal NET
(the PROMID trial), an antiproliferative efﬁcacy of octreotide
LAR has been conﬁrmed. The median time to tumor
progression was 14.3 months with octreotide LAR versus 6
months with placebo [23]. Based on these results, the use of
somatostatin analogs, especially octreotide LAR, is
recommended for antiproliferative purposes in functioning and
nonfunctioning small intestinal tumors (carcinoids) (II, A).
Somatostatin analogs are the recommended ﬁrst line therapy in
nonfunctioning as well as functioning progressive G1/G2
NETs. In contrast, in metastatic NEC G3 regardless of the site
of origin somatostatin analog treatment is not recommended
(III, B). There is also no indication for adjuvant therapy with
somatostatin analogs in NET G1/G2 irrespective of primary
tumor origin and potential microscopic metastases (III, B).
Other speciﬁc therapies in GEP-NETs are the mTOR-inhibitor
everolimus, alone or in combination with a somatostatin
analog. In the RADIANT-2 trial which was a randomized
phase III trial in patients with NETs (carcinoids), everolimus
demonstrated a signiﬁcant antitumor effect compared with
placebo by local review but not by central review (I, A).
Clinically beneﬁcial effects have been reported in carcinoid
patients. In patients with pancreatic NETs, totally 410 patients
who were randomized to either everolimus–octreotide or
placebo-octreotide, Radiant 3, signiﬁcant prolonged PFS, 11
versus 4.6 months, was noticed and everolimus is now
registered for treatment of pancreatic NETs worldwide (I, A)
[24, 25]. Tyrosine kinase inhibitors, sunitinib and pazopanib,
have demonstrated signiﬁcant antitumor efﬁcacy in pancreatic
NETs. In a randomized trial, sunitinib (37.5 mg/day) was
compared with placebo in 170 patients. The study was
Table 8. Gut endocrine tumors
Grade Mitotic count (10 HPF)a Ki67 index (5)b
Grading proposal for neuroendocrine tumors
G1 <2 ≤2
G2 2–20 3–20
G3 >20 >20
Tumor grading and classiﬁcation. ENETS grading proposal.
a10 HPF: 10 high power ﬁelds = 2 mm2, at least 40 ﬁelds (at ×40
magniﬁcation) evaluated in areas of highest mitotic density.
bMIB1 antibody; percentage of 2000 tumor cells in areas of highest nuclear
labeling.
Virchows Arch (2006) 449:395–401.
Virchows Arch (2007) 451:757–762.
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terminated early due to a signiﬁcant difference in efﬁcacy
between the treatment and the placebo arms. A signiﬁcant
longer PFS, 11 versus 5.5 months was noticed in favor of
sunitinib (I, A) [26]. Also sunitinib is now registered
worldwide for the treatment of pancreatic NETs. Pazopanib
has also demonstrated an antitumor effect in pancreatic NETs
in small phase II trials, alone or in combination with
octreotide or bevacizumab. Pazopanib may be better tolerated
than sunitinib in terms of side-effects.
systemic chemotherapy
Chemotherapy is recommended in NETs, metastatic NET G2
and in NEC G3 of any site. So far, results with systemic
chemotherapy in classical carcinoid tumors (G1) are poor with
response rates <15% (III, A). Systemic cytotoxics are indicated
in patients with inoperable progressive liver metastases from
G1/G2 pancreatic NETs using a combination of streptozotocin
and 5-ﬂuorouracil (5-FU)/doxorubicin with objective response
rates in the order of 35%–40% (II, B). From single
retrospective trials, temozolomide-based chemotherapy is
promising in pancreatic NETs either alone or combined with
capecitabine giving high partial remissions (40%–70%) (III, B).
Prospective randomized trials are warranted. In cases of liver
metastases involving high-grade NEC G3 regardless of the site
of the primary tumor combination chemotherapy, using
cisplatinum/etoposide is recommended early. There is no
established second-line therapy for poorly differentiated
endocrine carcinoma, but recent retrospective studies have
demonstrated the efﬁcacy of temozolomide alone or in
combination with capecitabine ± bevacizumab (III, B).
Encouraging results using either 5-FU i.v. or capecitabine
orally combined with oxaliplatin or irinotecan may also be an
option in the future (Table 9) [27–30].
peptide receptor-targeted radiotherapy
Promising data have evolved with regard to peptide receptor-
targeted radiotherapy (PRRT) in the treatment of NETs with
liver metastases using 90Yttrium and 177Lutetium labeled
DOTATOC or DOTATATE. PRRT can be considered in both
functioning and nonfunctioning NETs with positive
somatostatin receptor scintigraphy irrespective of the primary
tumor site. Based on phase II trials, more than 1000 patients in
total have been treated in Europe with objective response rates
ranging between 20% and 40% (III, A). Response rates are
higher in pancreatic compared with small intestinal NETs (III,
A). The highest [31] objective response rate has so far been
obtained in metastatic rectal NETs. Prospective randomized
trials are still lacking but in progress. A treatment algorithm is
depicted in Figure 1.
Table 9. Chemotherapy
Reference Type of tumor Regimen No. of
patients
Objective
response
Response duration
(months)
Median survival
(months)
Moertel et al. Pancreatic STZ 42 36 17 16.5
STZ–5-FU 42 63 17 26
Eriksson et al. Pancreatic STZ–5-FU or DOX 44 45 27.5 –
Moertel et al. Pancreatic STZ–DOX 36 69 18 26
STZ–5-FU 33 45 14 18
Cheng and
Saltz
Pancreatic STZ–DOX 16 6 18 –
McCollum
et al.
Pancreatic STZ–DOX 16 6 3.9 20.2
Kouvaraki et al. Pancreatic STZ–DOX–5-FU 84 39 9.3 40
Strosberg et al. Pancreatic Temozolomide–capecitabine 30 70 18 –
Moertel and
Hanley
Carcinoids 5-FU–cyclophosphamide 47 33 – –
STZ–5-FU 42 33 – –
Engstrom et al. Carcinoids STZ–5-FU 80 22 8 16
DOX 81 21 6.5 12
Bukowski et al. Carcinoids STZ–DOX–5-FU–cyclophosphamide 56 31 – –
STZ–5-FU–cyclophosphamide 9 22 – 10.8
Sun et al. Carcinoids DOX–5-FU 25 15.9 4.5 15.7
STZ–5-FU 27 16 5.3 24.3
Moertel et al. Poorly
differentiated
Cisplatin–etoposide 18 67 8 19
Mitry et al. Poorly
differentiated
Cisplatin–etoposide 41 42 9 15
Fjallskog et al. Poorly
differentiated
Cisplatin–etoposide 36 47 9 –
Welin et al. Poorly
differentiated
Temozolomide ± capecitabine ± bevacizumab 25 33 19 22
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response evaluation and follow-up
Follow-up investigations should include biochemical
parameters and conventional imaging. In patients with R0/R1
resected NET G1/G2, it is recommended that imaging is
performed every 3–6 months (CT or MRI), and in NEC G3,
every 2–3 months. Somatostatin receptor imaging, either
Octreoscan or PET/CT using 68Ga-DOTA-TOC/-NOC/-TATE
should be included in the follow-up and is recommended after
18–24 months if expression of somatostatin receptor 2a has
been proven on the tumor cells. In the case of rapid tumor
progression or if imaging information is lacking, it may be
necessary to re-biopsy liver metastases to re-assess the
proliferative activity. If chromogranin A is not elevated NSE
represents an alternative biomarker.
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